SYNAIRGEN PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.35 GBX | +8.89% |
|
+16.85% | +23.01% |
| 2023 | FTSE 100 Finishes Slightly Lower After Steady Session | DJ |
| 2023 | Synairgen names Phytome's Joseph Colliver as CFO | AN |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 13.59M 16.8M |
|---|---|---|---|---|---|
| Net income 2023 * | -9M -11.12M | Net income 2024 * | - | EV / Sales 2023 * | - |
| Net Debt 2023 * | 650K 803K | Net Debt 2024 * | 5.5M 6.8M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-1.41
x | P/E ratio 2024 * |
-
| Employees | 34 |
| Yield 2023 * |
88.9% | Yield 2024 * |
104% | Free-Float | 96.91% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +8.89% | ||
| 1 week | +16.85% | ||
| Current month | +44.26% | ||
| 1 month | +47.15% | ||
| 3 months | +22.70% | ||
| 6 months | +3.38% | ||
| Current year | +23.01% |
1 week
6.02
8.00
1 month
4.5010.00
Current year
4.0010.00
1 year
4.0014.30
3 years
4.00223.80
5 years
4.00260.00
10 years
4.00260.00
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
Joseph Colliver
DFI | Director of Finance/CFO | 43 | Nov. 05 |
Marcin Mankowski
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Shaw
CHM | Chairman | 59 | 03-05-31 |
Stephen Holgate
FOU | Founder | 77 | 03-05-31 |
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 7.35 | +8.89% | 319 |
| 24-04-22 | 6.75 | 0.00% | 64,104 |
| 24-04-19 | 6.75 | +2.27% | 316,825 |
| 24-04-18 | 6.6 | +2.33% | 247,694 |
| 24-04-17 | 6.45 | +2.54% | 402,705 |
Delayed Quote London S.E., April 23, 2024 at 04:00 am EDT
More quotes
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0675
GBP
Average target price
0.4
GBP
Spread / Average Target
+492.59%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.01% | 16.77M | |
| -0.02% | 42.11B | |
| +46.62% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
- Stock Market
- Equities
- SNG Stock
